- Home
- BRN vs BCDA Comparison
BRN vs BCDA Comparison
Compare BRN & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRN
- BCDA
- Stock Information
- Founded
- BRN 1956
- BCDA N/A
- Country
- BRN United States
- BCDA United States
- Employees
- BRN N/A
- BCDA N/A
- Industry
- BRN Oil & Gas Production
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- BRN Energy
- BCDA Health Care
- Exchange
- BRN Nasdaq
- BCDA Nasdaq
- Market Cap
- BRN 13.0M
- BCDA 11.3M
- IPO Year
- BRN N/A
- BCDA N/A
- Fundamental
- Price
- BRN N/A
- BCDA $1.42
- Analyst Decision
- BRN
- BCDA Strong Buy
- Analyst Count
- BRN 0
- BCDA 1
- Target Price
- BRN N/A
- BCDA $25.00
- AVG Volume (30 Days)
- BRN 38.5K
- BCDA 1.6M
- Earning Date
- BRN 08-13-2025
- BCDA 11-12-2025
- Dividend Yield
- BRN N/A
- BCDA N/A
- EPS Growth
- BRN N/A
- BCDA N/A
- EPS
- BRN N/A
- BCDA N/A
- Revenue
- BRN $18,073,000.00
- BCDA N/A
- Revenue This Year
- BRN N/A
- BCDA N/A
- Revenue Next Year
- BRN N/A
- BCDA N/A
- P/E Ratio
- BRN N/A
- BCDA N/A
- Revenue Growth
- BRN N/A
- BCDA N/A
- 52 Week Low
- BRN $1.08
- BCDA $1.00
- 52 Week High
- BRN $2.32
- BCDA $3.20
- Technical
- Relative Strength Index (RSI)
- BRN 58.93
- BCDA 37.03
- Support Level
- BRN $1.17
- BCDA $1.27
- Resistance Level
- BRN $1.39
- BCDA $1.42
- Average True Range (ATR)
- BRN 0.09
- BCDA 0.10
- MACD
- BRN 0.01
- BCDA 0.01
- Stochastic Oscillator
- BRN 70.65
- BCDA 50.50
About BRN Barnwell Industries Inc.
Barnwell Industries Inc is an oil and gas firm. Its areas of operations include acquiring, developing, producing, and selling oil and natural gas. The company acquires and develops crude oil and natural gas assets. The company's operating segment includes Oil and natural gas, Contract drilling, Land investment, and Others. It generates maximum revenue from the Oil and natural gas segment. It operates in two geographical segments the United States, which generates a majority of revenue, and Canada.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).